Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | QPCT | Q16769 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | NMT1 | P30419 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1626212 | 0.83 | HPGD (0.49) | ACHEALDH1A1HRH3GPR119 | |
| SCHEMBL3425233 | 0.82 | HRH4 (0.42) | KDM4EHRH4ACHEALDH1A1HRH3 | |
| SCHEMBL16762141 | 0.81 | ALDH1A1 (0.45) | KDM4EACHEALDH1A1L3MBTL1POLB | |
| SCHEMBL1628166 | 0.80 | ALDH1A1 (0.49) | KDM4EALDH1A1HRH3ATM | |
| SCHEMBL3428038 | 0.80 | HPGD (0.51) | KDM4EHRH4ALDH1A1QPCT | |
| SCHEMBL3422680 | 0.79 | HRH4 (0.45) | HRH4ACHEHRH3QPCTNMT1 | |
| SCHEMBL1627975 | 0.79 | HRH4 (0.43) | HRH4ACHEGPR119QPCTNMT1 | |
| SCHEMBL1625928 | 0.79 | HSD11B1 (0.44) | HRH4HRH3 | |
| SCHEMBL3423689 | 0.78 | HRH4 (0.40) | HRH4ACHEALDH1A1HRH3QPCT | |
| SCHEMBL3424922 | 0.78 | HRH4 (0.48) | HRH4HRH3GPR119QPCTNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | disclosed |
| US-8039498-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-10-18 | — | — | US | disclosed |
| US-8017639-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-8017600-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | disclosed |
| US-7956071-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956066-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7956057-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-07 | — | — | US | disclosed |
| US-7951808-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7928131-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-19 | — | — | US | disclosed |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | BUZARD DANIEL J | 2010-10-14 | — | — | US | disclosed |
| US-20070173512-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173509-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070173510-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | disclosed |
| EP-1673348-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-28 | — | — | EP | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005044807-A2 | BENZOIMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050070550-A1 | Benzoimidazole compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070550-A1 | Benzoimidazole compounds | HRH4, HRH3, BRD4 | KDM4E 1377/4885HRH4 1/4885ACHE 4151/4885 |
| US-20070173512-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | KDM4E 1208/4885HRH4 1/4885ACHE 2440/4885 |
| US-20070173509-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | KDM4E 1208/4885HRH4 1/4885ACHE 2440/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | KDM4E 1208/4885HRH4 1/4885ACHE 2440/4885 |
| US-20070173510-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | KDM4E 1208/4885HRH4 1/4885ACHE 2440/4885 |
| US-20100261899-A1 | IMIDAZOLE COMPOUNDS | HRH4, HRH3, HRH2 | KDM4E 1208/4885HRH4 1/4885ACHE 2440/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | KDM4E 1208/4885HRH4 1/4885ACHE 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.